Lessig Megan Kinnear
Division of Endocrinology at The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
J Pediatr Oncol Nurs. 2009 Jul-Aug;26(4):208-16. doi: 10.1177/1043454209340316.
Despite aggressive research and treatment, high-risk neuroblastoma continues to have a devastating mortality rate of more than 40%. Research conducted over the past 2 decades has shown that the radioisotope (131)I-MIBG (metaiodobenzylguanidine) is effective in the treatment of this difficult patient population. The purpose of this article is to review the diagnosis, staging, and conventional treatment of neuroblastoma and to understand the mechanism of action of MIBG and ( 131)I-MIBG. This article also reviews treatments for high-risk neuroblastoma patients and analyzes recent research studies that used (131)I-MIBG to better define the role of this treatment in high-risk neuroblastoma patients. In addition, this article explores the role of the advanced practice nurse to serve at the forefront in the implementation of a multidisciplinary ( 131)I-MIBG treatment program.
尽管进行了积极的研究和治疗，但高危神经母细胞瘤的死亡率仍高达40%以上，令人痛心。过去20年的研究表明，放射性同位素（131）I-间碘苄胍（MIBG）对治疗这类棘手的患者群体有效。本文旨在综述神经母细胞瘤的诊断、分期和传统治疗方法，了解MIBG和（131）I-MIBG的作用机制。本文还综述了高危神经母细胞瘤患者的治疗方法，并分析了近期使用（131）I-MIBG的研究，以更好地界定这种治疗方法在高危神经母细胞瘤患者中的作用。此外，本文还探讨了高级执业护士在实施多学科（131）I-MIBG治疗方案中发挥前沿作用的情况。
